Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/16390
Full metadata record
DC FieldValueLanguage
dc.contributor.authorRoberts, Jason A-
dc.contributor.authorChoi, Gordon YS-
dc.contributor.authorJoynt, Gavin M-
dc.contributor.authorPaul, Sanjoy K-
dc.contributor.authorDeans, Renae-
dc.contributor.authorPeake, Sandra-
dc.contributor.authorCole, Louise-
dc.contributor.authorStephens, Dianne-
dc.contributor.authorBellomo, Rinaldo-
dc.contributor.authorTurnidge, John-
dc.contributor.authorWallis, Steven C-
dc.contributor.authorRoberts, Michael S-
dc.contributor.authorRoberts, Darren M-
dc.contributor.authorLassig-Smith, Melissa-
dc.contributor.authorStarr, Therese-
dc.contributor.authorLipman, Jeffrey-
dc.date.accessioned2016-10-27T02:33:09Z-
dc.date.available2016-10-27T02:33:09Z-
dc.date.issued2016-03-01-
dc.identifier.citationBMC Infectious Diseases 2016; 16: 103en_US
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/16390-
dc.description.abstractBACKGROUND: Optimal antibiotic dosing is key to maximising patient survival, and minimising the emergence of bacterial resistance. Evidence-based antibiotic dosing guidelines for critically ill patients receiving RRT are currently not available, as RRT techniques and settings vary greatly between ICUs and even individual patients. We aim to develop a robust, evidence-based antibiotic dosing guideline for critically ill patients receiving various forms of RRT. We further aim to observe whether therapeutic antibiotic concentrations are associated with reduced 28-day mortality. METHODS/DESIGN: We designed a multi-national, observational pharmacokinetic study in critically ill patients requiring RRT. The study antibiotics will be vancomycin, linezolid, piperacillin/tazobactam and meropenem. Pharmacokinetic sampling of each patient's blood, RRT effluent and urine will take place during two separate dosing intervals. In addition, a comprehensive data set, which includes the patients' demographic and clinical parameters, as well as modality, technique and settings of RRT, will be collected. Pharmacokinetic data will be analysed using a population pharmacokinetic approach to identify covariates associated with changes in pharmacokinetic parameters in critically ill patients with AKI who are undergoing RRT for the five commonly prescribed antibiotics. DISCUSSION: Using the comprehensive data set collected, the pharmacokinetic profile of the five antibiotics will be constructed, including identification of RRT and other factors indicative of the need for altered antibiotic dosing requirements. This will enable us to develop a dosing guideline for each individual antibiotic that is likely to be relevant to any critically ill patient with acute kidney injury receiving any of the included forms of RRT. TRIAL REGISTRATION: Australian New Zealand Clinical Trial Registry ( ACTRN12613000241730 ) registered 28 February 2013.en_US
dc.subjectAcute Kidney Injuryen_US
dc.subjectAnti-Bacterial Agentsen_US
dc.subjectRenal Replacement Therapyen_US
dc.subjectSepsisen_US
dc.titleSaMpling Antibiotics in Renal Replacement Therapy (SMARRT): an observational pharmacokinetic study in critically ill patientsen_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleBMC Infectious Diseasesen_US
dc.identifier.affiliationThe Queen Elizabeth Hospital, Adelaide, South Australia, Australiaen
dc.identifier.affiliationBurns Trauma and Critical Care Research Centre, The University of Queensland, Royal Brisbane and Women’s Hospital, Herston, Queensland, Australiaen_US
dc.identifier.affiliationRoyal Brisbane & Women’s Hospital, Herston, Queensland, Australiaen_US
dc.identifier.affiliationPrince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, Special Administrative Region, Chinaen_US
dc.identifier.affiliationClinical Trials & Biostatistics Unit, QIMR Berghofer, Herston, Queensland, Australiaen_US
dc.identifier.affiliationNepean Hospital, Kingswood, NSW, Australiaen_US
dc.identifier.affiliationRoyal Darwin Hospital, Darwin, Northern Territory, Australiaen_US
dc.identifier.affiliationAustin Health, Heidelberg, Victoria, Australiaen_US
dc.identifier.affiliationRoyal Children’s Hospital, Herston, Queensland, Australiaen_US
dc.identifier.affiliationTherapeutics Research Unit, The University of Queensland, Queensland, Australiaen_US
dc.type.studyortrialClinical Trialen_US
dc.identifier.pubmedurihttps://pubmed.ncbi.nlm.nih.gov/26932762en_US
dc.identifier.doi10.1186/s12879-016-1421-6en_US
dc.type.contentTexten_US
dc.type.austinJournal Articleen_US
local.name.researcherBellomo, Rinaldo
item.openairetypeJournal Article-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.grantfulltextopen-
item.fulltextWith Fulltext-
item.cerifentitytypePublications-
crisitem.author.deptIntensive Care-
crisitem.author.deptData Analytics Research and Evaluation (DARE) Centre-
Appears in Collections:Journal articles
Files in This Item:
File Description SizeFormat 
art%3A10.1186%2Fs12879-016-1421-6.pdf617.38 kBAdobe PDFThumbnail
View/Open
Show simple item record

Page view(s)

16
checked on Mar 27, 2024

Download(s)

12
checked on Mar 27, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.